Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2003-02-07
2010-11-09
Szperka, Michael (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S141100, C424S145100, C530S388250, C530S388260, C435S337000, C435S338000
Reexamination Certificate
active
07829095
ABSTRACT:
A monoclonal antibody which inhibits the blood clotting factor VII-activating protease and its proenzyme and a blood clotting factor VII-activating protease, stabilized by the addition of said monoclonal antibody, and its proenzyme are described. A suitable monoclonal antibody is produced by hybridoma cell line DSM ACC 2533. The application of the inhibitory, monoclonal antibody in the stabilization of blood clotting preparations and in preparations for reducing the coagulability of the blood is disclosed.
REFERENCES:
patent: 5175087 (1992-12-01), Ranby et al.
patent: 5658568 (1997-08-01), Bagshawe
patent: 5968759 (1999-10-01), Roemisch et al.
patent: 6528299 (2003-03-01), Römisch et al.
patent: 6831167 (2004-12-01), Becker et al.
patent: 2002/0110552 (2002-08-01), Roemisch et al.
patent: 2003/0077271 (2003-04-01), Kannemeier et al.
patent: 2003/0124622 (2003-07-01), Roemisch et al.
patent: 2003/0125247 (2003-07-01), Rosen et al.
patent: 2004/0083187 (2004-04-01), Andreoli et al.
patent: 2004/0186277 (2004-09-01), Roemisch et al.
patent: 2005/0032109 (2005-02-01), Roemisch et al.
patent: 2005/0202002 (2005-09-01), Roemisch et al.
patent: 199 26 531.3 (1999-06-01), None
patent: 199 03 693 (1999-10-01), None
patent: 199 37 218 (2001-02-01), None
patent: 199 37 219 (2001-02-01), None
patent: 100 36 641 (2002-02-01), None
patent: 100 52 319 (2002-04-01), None
patent: 100 23 923 (2002-12-01), None
patent: 0 952 215 (1999-10-01), None
patent: 1 059 359 (2000-12-01), None
patent: 1 074 615 (2001-02-01), None
patent: 1 074 616 (2001-02-01), None
patent: 1 182 258 (2002-02-01), None
Choi-Miura et al., “Proteolytic activation and inactivation of the serine protease activity of plasma hyaluronan binding protein,” 2001, Biol. Pharm. Bull. 24:448-452.
Choi-Miura, “Novel human plasma proteins, IHRP (acute phase protein) and PHBP (serine protease), which bind glycosaminoglycans,” 2004, Curr. Med. Chem. Cardiovascular and hematological Agents 2:239-248.
Kipriyanov et al., “Generation of recombinant Antibodies,” Molecular Biotechnology, 1999, 12:173-201.
Romisch et al., “Quantitation of the factor VII and single chain plasminogen activator-activating protease in plasma of healthy subjects,” Blood Coagulation and Fibrinolysis, 2001, 12:375-383.
K. Laake et al., “Activation of Purified Plasma Factor VII by Human Plasmin, Plasma Kallikrein, And Activated Components of the Human Intrinsic Blood Coagulation System,”Thrombosis Research, vol. 5 (6): 759-772 (1974).
N-H. Choi-Miura, et al., “Purification and Characterization of a Novel Hyaluronan-Binding Protein (PHBP) From Human Plasma: It Has Three EGF, a Kringle and a Serine Protease Domain, Similar to Hepatocyte Growth Factor Activator,”J. Biochem, vol. 119 (6): 1157-1165 (1996).
K. Hashimoto et al., “Cloning of the cDNA for a Mouse Homologue of Human PHBP: A Novel Hyaluronan-Binding Protein,”Biol. Pharm. Bulletin, vol. 20(11): 1127-1130 (1997).
J. Sumiya et al., “Isolation and Characterization of the Plasma Hyaluronan-Binding Protein (PHBP) Gene (HABP2),”J. Biochem., vol. 122: 983-990 (1997).
J. Roemisch et al., “A Protease Isolated From Plasma Which Activates FVII In a Tissue Factor Independent Manner But Inactivates FV and FVIII,”Annals of Hematology, vol. 78 (1) Suppl. 1 (Abstract) (1999).
M. Etscheid et al.,43rdAnnual Meeting of the GTH; Supplement I to vol. 78 A42, P030, (1999).
A. Hunfeld et al., “Detection of a Novel Plasma Serine Protease During Purification of Vitamin K-Dependent Coagulation Factors,”FEBS Letters, vol. 1 (456): 290-294 (1999).
J. Roemisch et al., “A Protease Isolated From Human Plasma Activating Factor VII Independent of Tissue Factor,”Blood Coagulation and Fibrinolysis, vol. 10 (8): 471-479 (1999).
J. Roemisch et al., “The FVII Activating Protease Cleaves Single-Chain Plasminogen Activators,”Haemostasis, vol. 29: 292-299 (1999).
J. Roemisch et al., “The FVII Activating Protease Mediates Fibrinolytic Effects Activating Single-Chain Plasminogen Activators,”Annals of Hematology, vol. 78 (1): 24-27 (Abstract) (1999).
A. Vostrov et al., “Plasma Hyaluronan-binding Protein Is a Serine Protease,”J. Biological Chemistry, vol. 275 (30): 22978-22985 (2000).
C. Kannemeier et al., “Factor VII and Single-Chain Plaminogen Activator-Activating Protease: Activation and Autoactivation of the Proenzyme,”Eur. J. Biochem., 268: 3789-3796 (2001).
J. Roemisch et al., “Factor VII Activating Protease (FSAP): A Novel Protease in Hemostasis,”Biol. Chem., 383: 119-1124 (2002).
Derwent Abstract of EP 1 074 615, 2001.
Derwent Abstract of EP 1 074 616, 2001.
Derwent Abstract of EP 1 182 258, 2001.
Feussner Annette
Kannemaier Christian
Lang Wiegand
Muth-Naumann Gudrun
Nakazawa Fumie
CSL Behring GmbH
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Szperka Michael
LandOfFree
Inhibitory monoclonal antibody against blood clotting factor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitory monoclonal antibody against blood clotting factor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitory monoclonal antibody against blood clotting factor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4174137